Home » Stocks » Annexon Biosciences

Annexon Biosciences, Inc. (ANNX)

Stock Price: $24.59 USD -1.64 (-6.25%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 938.06M
Revenue (ttm) n/a
Net Income (ttm) -44.83M
Shares Out 38.15M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $24.59
Previous Close $26.23
Change ($) -1.64
Change (%) -6.25%
Day's Open 26.20
Day's Range 24.36 - 26.97
Day's Volume 215,822
52-Week Range 15.33 - 31.84

More Stats

Market Cap 938.06M
Enterprise Value 813.30M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.15M
Float 25.61M
EPS (basic) n/a
EPS (diluted) -1.18
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.19M
Short Ratio 3.73
Short % of Float 4.65%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 29.47
Revenue n/a
Operating Income n/a
Net Income -44.83M
Free Cash Flow n/a
Net Cash 124.76M
Net Cash / Share 3.27
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.14%
ROE -63.39%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(34.20% upside)
Current: $24.59
Target: 33.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-32.52-19.15
Net Income-37.18-18.30
Shares Outstanding0.430.40
Earnings Per Share-88.30-45.89
Operating Cash Flow-28.36-17.19
Capital Expenditures-0.27-0.02
Free Cash Flow-28.63-17.21
Cash & Equivalents43.9344.18
Net Cash / Debt43.9344.18
Book Value-100-64.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Annexon Biosciences, Inc.
Country United States
Employees 30
CEO Douglas Love

Stock Information

Ticker Symbol ANNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANNX
IPO Date July 24, 2020


Annexon, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.